All In Biotech

Drug Trial Radar · NCT06111274

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Oct 17, 2023

Primary completion

Dec 30, 2025

Study completion Dec 29, 2026

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer. * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer. Participants will be asked to complete the study procedures: * Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B. * Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. * Complete the study procedures specified in the protocol, which is guided by researchers.

Conditions

  • Advanced Pancreatic Cancer

Interventions

  • Pimicotinib (ABSK021)Drug

    The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Event OccuranceTime frame: From the day signed informed consent form to day 90 after the end of cycle 8 (each cycle is 21 days)
  2. Objective Response Rate (ORR)Time frame: From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Ha’erbin, China · Recruiting

  • Shanghai East Hospital Tongji University

    Shanghai, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of science and technolog

    Wuhan, China · Recruiting

  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.